Hypoxia Mimetic Activity Of VCE-004.8, A Cannabidiol Quinone Derivative: Implications For Multiple Sclerosis Therapy

Multiple Sclerosis (MS)

Key Findings

VCE-004.8 treatments prevented demyelination, axonal damage, and immune cells infiltration. In addition, VCE-004.8 downregulated the expression of several genes closely associated with MS physiopathology, including those underlying the production of chemokines, cytokines, and adhesion molecules.

Information and Links


Link: Hypoxia Mimetic Activity Of VCE-004.8, A Cannabidiol Quinone Derivative: Implications For Multiple Sclerosis Therapy

Year: 2018

DOI: 10.1186/s12974-018-1103-y.


Ratings

(How Ratings Work)

Multiple Sclerosis (MS) — 1


Possibility of efficacy for cannabis in treatment of Multiple Sclerosis (MS) according to the results found in this study.

Drugs Used

VCE-004.8, an aminoquinone derivative of cannabidiol (CBD), is a dual PPARγ and CB2 agonist with potent anti-inflammatory activity.